Compare Citius Pharmaceuticals Inc (CTXR) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nasdaq Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nasdaq Inc trades at $93.65 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 3790.7× Citius Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nasdaq Inc for 126 Days on average.
| CTXR | NDAQ | |
|---|---|---|
Market Cap | $13.62M | $51.63B |
Volume | 132,438 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $1.82 | $100.98 |
52-Week Low | $0.48 | $76.85 |
Typical Hold Time | 17 Days | 126 Days |
Enterprise Value | $3.79M | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Nasdaq Inc. (NDAQ) trades at $92.37, up 0.48% today, with a bullish technical signal from moving averages and strong fundamental performance including a 21.64% net income margin and consistent earnings beats. Recent news highlights growth in its Financial Technology business, such as HSBC adopting Nasdaq Calypso for derivatives clearing (GlobeNewsWire, 2026-09-28).
The outlook is positive with a consensus price target of $110.43, implying 19.6% upside, supported by robust profitability and AI-driven initiatives. Risks include high valuation multiples and market volatility, but analyst sentiment is strongly bullish with 61% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
